Tuberculosis, an ongoing pandemic, highlights and exacerbates global disparities. With the prevailing model of standardised treatment in vertical health programmes, it is unsurprising that ...

The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...

Oxford-based Nucleome – which is developing an atlas of the dark genome and is focusing initially on finding drugs for autoimmune ... to genetics in a number of human immune cell types and ...

When Adam Rodman was a second-year medical student in the 2000s, he visited the library for a patient whose illness had left ...

The advent of high-throughput sequencing technology has enabled the decoding of the entire human genome ... These drugs can precisely target cancer cells carrying BRCA mutations, leading to more ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Pioneering the World's 1st Dark Matter Cancer Immunotherapy UbiVac's DPV-001 is the World's 1st Dark Matter Cancer Immunotherapy in the Cli ...

Glioblastoma has long resisted treatment, but scientists may have found a breakthrough by leveraging the body's own ...

Finally, the widespread deployment of AI will catalyze change in almost every aspect of healthcare, including using AI to ...

After the rejection of Hutchmed’s treatment, despite the efforts to include a bridging trial, the FDA seems to have drawn a line in the sand, effectively requiring multiregional clinical trials ...

Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy. But new ...

However, there is little use for large-scale genome or ... access to available drugs on the market (or in clinical development) that are likely to be appropriate for the treatment of that subclass ...